When 28-year-old Amina Hassan walked into University College London Hospital for a single infusion of a reengineered immune therapy, she had spent over a decade battling severe lupus that had resisted every available treatment. Her kidneys were failing, her joints ached constantly, and her quality of life had dwindled to hospital visits and symptom management. Today, just months after receiving obe-cel—a CAR T-cell therapy developed by Autolus Therapeutics and pioneered in a UCL-led trial—Amina is in remission, her kidney function stabilizing, and her life quietly returning to normal. Her story is one of nine early patients in the CARLYSLE study, but it echoes a growing hope: that autoimmune diseases like lupus may no longer be lifelong sentences, but conditions that can be reset.
Lupus, a chronic autoimmune disorder affecting at least 5 million people worldwide—90% of them women—occurs when the immune system turns against healthy tissues, damaging organs like the kidneys, heart, and lungs. For those with refractory systemic lupus erythematosus (SLE), standard therapies often fail, leaving few options. That’s why the early results from the Phase I CARLYSLE trial, presented at the EULAR 2026 Congress, are so significant. The therapy, obecabtagene autoleucel (obe-cel), reprograms a patient’s own T cells to target CD19-positive B cells, the very cells driving autoimmune attacks. By eliminating these cells—including antibody-producing plasmablasts—the treatment aims to reset the immune system rather than merely suppress it.
The trial enrolled nine adults aged 12 to 65 with severe, treatment-resistant lupus, most suffering from lupus nephritis. After lymphodepletion, they received a single infusion of obe-cel at one of two dose levels. What’s remarkable is not just the clinical response, but the safety. Not a single patient developed immune effector cell-associated neurotoxicity syndrome (ICANS), and there were no cases of moderate or severe cytokine release syndrome (CRS)—common and dangerous side effects in other CAR T therapies. One case of liver injury occurred but resolved completely. Other side effects, like neutropenia and infections, were manageable and expected.
In the lower-dose group, 5 out of 6 patients achieved remission by standard lupus criteria, with disease activity scores dropping rapidly. Anti-double-stranded DNA antibodies—key markers of lupus activity—plummeted, while complement levels, which had been dangerously low, rebounded. For those with kidney involvement, the results were especially promising: several achieved complete or partial renal responses, with proteinuria decreasing and kidney function improving.
Even more telling was what happened in the immune system post-infusion. CAR T cells expanded robustly, and B cells were deeply depleted. When they returned—typically between three and six months—they were mostly early-stage, naïve cells, not the mature, autoreactive types that drive disease. This suggests a true immune reset, not just suppression.
Dr. Claire Roddie, a trial investigator from the UCL Cancer Institute and UCLH consultant hematologist, put it simply: "For patients living with severe lupus that has not responded to existing treatments, the options can feel like running out. This therapy offers a new horizon." With longer follow-up and expanded trials on the horizon, obe-cel may soon offer not just remission, but the chance to reclaim a life.